COMPANY PROFILE

Spectrumedics

Explore full profile

A medical equipment manufacturing

Singapore, SingaporeFounded 2019Health Tech & Medtech

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Spectrumedics

Spectrumedics is a medical device company focused on developing minimally invasive solutions for cardiovascular diseases. Founded in 2018 by Al Ray Tabiliran, Elynn Phang, and Peng Huiqun, the company is headquartered in Singapore with significant operations in Shanghai, China. Spectrumedics operates in the surgical and medical device market, specifically targeting the treatment of arterial vascular calcification. The firm's business model centers on the manufacturing and sale of therapeutic devices to healthcare professionals and facilities that perform interventional therapy and surgery for heart conditions.

The company's flagship product is the "Sonico" intravascular shockwave balloon catheter system, designed to treat stenotic lesions in peripheral and coronary arteries. This system utilizes shockwave energy to break up calcified plaque buildups within the arteries. The Sonico system is comprised of two primary components: a semi-compliant balloon catheter with electrohydraulic lithotripsy emitters and a portable control system. The emitters convert electrical energy into shockwaves that disrupt calcium deposits, while the catheter delivers a specified dosage of shockwaves as programmed by the control system, which helps to minimize risk to the healthier parts of the vessel. The company's first independently developed product, the Sonico-PX, began clinical trials for peripheral and coronary intravascular lithotripsy (IVL) in late 2021.

Since its inception, Spectrumedics has achieved notable financial milestones. The company secured $15 million in a Series A funding round on May 7, 2022, led by Legend Capital with participation from BC Capital, Yangyun Capital, and Wilder Capital. This capital infusion was intended to support the ongoing clinical research and development of its shockwave catheter products, enhance its technology platform, expand its product pipeline, and increase production capacity. The company's legal entity is SPECTRUMEDICS INTERNATIONAL PTE. LTD., incorporated on June 30, 2020.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Singapore, Singapore
Employees: 12
Open positions: None listed
Dealroom signal: 51.9/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Surgery, Spinout, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	May 2022	$14M	$55M	Legend Capital · BC Capital · Wide Capital · Sunmed Capital	↗
SPINOUT✓Other financing	Jan 2019	$0	—	National University of Singapore	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Spectrumedics website traffic

Latest recorded traffic for Spectrumedics is 630 monthly website visits, up 70.3% over the last three months. Spectrumedics's team grew 33.3% over the past year.

Latest monthly visits630 3-month web change+70.3% 1-year team growth+33.3%

Monthly website visitsFeb 2023–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ENEcho NeurotechnologiesDeveloping neuroscience products to restore conversational communication for patients with severe disabilities	San Francisco, United States	Operational	—	$50M	$200M
ARArtifexInnovative artificial vascular grafts with patented cellulose coating and alloy scaffold for coronary and peripheral bypasses	Vienna, Austria	Operational
APApproximaThe first minimally invasive treatment tailored for the tricuspid valve	Milan, Italy	Operational
RARainMedA vascular interventional surgical robot developer focused on the development of coronary angiography systems	Suzhou Shi, China	Operational
CRCornerstone RoboticsA surgical robot research and development company	Shenzhen, China	Operational
VCVesalius CardiovascularInnovative pre-clinical medical devices specializing in mitral regurgitation solutions for degenerative and functional mitral valve diseases	Vancouver, Canada	Operational
COCohesysRedefining fracture repair with BoneTape by eliminating the need for conventional plate and screw based care	Toronto, Canada	Operational
CIClarix ImagingSpecimen imaging for breast cancer surgery, providing unparalleled 3D visualization of lumpectomy specimens with VSI-360™, improving the correlation between interpretation and surgical pathology, and supported by decades	Chicago, United States	Operational